Format

Send to

Choose Destination
Clin Infect Dis. 2013 Jun;56(12):1779-88. doi: 10.1093/cid/cit178. Epub 2013 Mar 19.

Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections?

Author information

1
Department of Microbiology and Infectious Diseases, Royal Prince Alfred Hospital, Camperdown, Sydney, Australia. sebastian.vanhal@sswahs.nsw.gov.au

Abstract

For more than 4 decades, vancomycin has been the antibiotic of choice for methicillin-resistant Staphylococcus aureus (MRSA) infections. Recently, infections due to isolates with high but susceptible vancomycin minimum inhibitory concentrations have been associated with additional treatment failures and patient mortality. These poorer outcomes may in part be explained by the inability of attaining appropriate vancomycin levels in these patients. However, assumptions that these poor outcomes are solely due to failure to achieve optimal serum levels of vancomycin are premature. The availability of effective alternatives further erodes the position of vancomycin as first-line therapy. The emergence of resistance and cost considerations, however, favor a more measured approach when using alternative antimicrobials. Collectively, the current available data suggest that the optimal therapy for MRSA infections remains unclear. In the absence of further data, the Infectious Diseases Society of America guidelines remain relevant and inform clinicians of best practice for treating patients with MRSA infections.

KEYWORDS:

AUC/MIC targets; MRSA, hVISA, VISA; Staphylococcus aureus; minimum inhibitory concentration (MIC); vancomycin

Comment in

PMID:
23511300
PMCID:
PMC3658366
DOI:
10.1093/cid/cit178
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center